Enhanced efficacy of combination therapy with adeno‑associated virus-delivered pigment epithelium-derived factor and cisplatin in a mouse model of Lewis lung carcinoma

He,Sha-Sha; Wu,Qin-Jie; Gong,Chang Yang; Luo,Shun-Tao; Zhang,Shuang; Li,Meng; Lu,Lian; Wei,Yu-Quan; Yang,Li

doi:10.3892/mmr.2014.2117

Enhanced efficacy of combination therapy with adeno‑associated virus-delivered pigment epithelium-derived factor and cisplatin in a mouse model of Lewis lung carcinoma

Authors:
- Sha-Sha He
- Qin-Jie Wu
- Chang Yang Gong
- Shun-Tao Luo
- Shuang Zhang
- Meng Li
- Lian Lu
- Yu-Quan Wei
- Li Yang
View Affiliations

Affiliations: State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: April 4, 2014 https://doi.org/10.3892/mmr.2014.2117
Pages: 2069-2076
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pigment epithelium-derived factor (PEDF) is a potent inhibitor of angiogenesis, and the antitumor effect of adeno-associated virus (AAV)-mediated PEDF expression has been demonstrated in a range of animal models. The combined treatment of low-dose chemotherapy and gene therapy inhibits the growth of solid tumors more effectively than current traditional therapies or gene therapy alone. In the present study, the effect of treatment with an AAV2 vector harboring the human PEDF (hPEDF) gene in combination with low-dose cisplatin on the growth of Lewis lung carcinoma (LLC) in mice was assessed. LLC cells were infected with AAV-enhanced green fluorescent protein (EGFP) in the presence or absence of cisplatin, and then the effect of cisplatin on AAV-mediated gene expression was evaluated by image and flow cytometric analysis. Tumor growth, survival time, vascular endothelial growth factor (VEGF) expression, microvessel density (MVD) and apoptotic index were analyzed in C57BL/6 mice treated with AAV-hPEDF, cisplatin or cisplatin plus AAV-hPEDF. The results of the present study provide evidence that cisplatin treatment is able to enhance AAV-mediated gene expression in LLC cells. In addition, the combined treatment of cisplatin plus AAV‑hPEDF markedly prolonged the survival time of the mice and inhibited tumor growth, resulting in significant suppression of tumor angiogenesis and induction of tumor apoptosis in vivo, and also protected against cisplatin-related toxicity. These findings suggest that combination of AAV-hPEDF and cisplatin has potential as a novel therapeutic strategy for lung cancer.

View Figures

View References

1	Adam M, Bayer C, Henke J, et al: Tirapazamine plus cisplatin and irradiation in a mouse model: improved tumor control at the cost of increased toxicity. J Cancer Res Clin Oncol. 134:137–146. 2008. View Article : Google Scholar : PubMed/NCBI
2	Verweij J, de Wit R and de Mulder PH: Optimal control of acute cisplatin-induced emesis. Oncology. 53(Suppl 1): 56–64. 1996. View Article : Google Scholar
3	Jiang M, Liu Z, Xiang Y, et al: Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma. BMC Cancer. 11:542011. View Article : Google Scholar : PubMed/NCBI
4	Kanazawa T, Mizukami H, Okada T, et al: Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther. 10:51–58. 2003. View Article : Google Scholar : PubMed/NCBI
5	Wang Y, Huang F, Cai H, et al: The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma. J Cancer Res Clin Oncol. 136:1827–1837. 2010. View Article : Google Scholar
6	Monahan PE, Jooss K and Sands MS: Safety of adeno-associated virus gene therapy vectors: a current evaluation. Expert Opin Drug Saf. 1:79–91. 2002. View Article : Google Scholar : PubMed/NCBI
7	Wagner JA, Reynolds T, Moran ML, et al: Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet. 351:1702–1703. 1998. View Article : Google Scholar : PubMed/NCBI
8	Muramatsu S, Fujimoto K, Ikeguchi K, et al: Behavioral recovery in a primate model of Parkinson’s disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine synthesizing enzymes. Hum Gene Ther. 13:345–354. 2002.PubMed/NCBI
9	Kay MA, Manno CS, Ragni MV, et al: Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 24:257–261. 2000. View Article : Google Scholar : PubMed/NCBI
10	Becerra SP, Sagasti A, Spinella P and Notario V: Pigment epithelium-derived factor behaves like a noninhibitory serpin. Neurotrophic activity does not require the serpin reactive loop. J Biol Chem. 270:25992–25999. 1995. View Article : Google Scholar : PubMed/NCBI
11	Broadhead ML, Dass CR and Choong PF: In vitro and in vivo biological activity of PEDF against a range of tumours. Expert Opin Ther Targets. 13:1429–1438. 2009. View Article : Google Scholar : PubMed/NCBI
12	Tombran-Tink J and Barnstable CJ: PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci. 4:628–636. 2003. View Article : Google Scholar : PubMed/NCBI
13	Dawson D, Volpert OV, Gillis P, et al: Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 285:245–248. 1999. View Article : Google Scholar : PubMed/NCBI
14	Fernandez-Garcia NI, Volpert OV and Jimenez B: Pigment epithelium-derived factor as a multifunctional antitumor factor. J Mol Med (Berl). 85:15–22. 2007. View Article : Google Scholar : PubMed/NCBI
15	Jaffe EA, Nachman RL, Becker CG and Minick CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 52:2745–2756. 1973. View Article : Google Scholar : PubMed/NCBI
16	He SS, Shi HS, Yin T, et al: AAV-mediated gene transfer of human pigment epithelium-derived factor inhibits Lewis lung carcinoma growth in mice. Oncol Rep. 27:1142–1148. 2012.PubMed/NCBI
17	Wu X, Dong X, Wu Z, Cao H, Niu D, et al: A novel method for purification of recombinant adenoassociated virus vectors on a large scale. Chinese Sci Bull. 46:485–488. 2001. View Article : Google Scholar
18	Pang X, Yi Z, Zhang X, et al: Acetyl-11-ketob-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res. 69:5893–5900. 2009. View Article : Google Scholar : PubMed/NCBI
19	Alexander IE, Russell DW and Miller AD: DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J Virol. 68:8282–8287. 1994.PubMed/NCBI
20	Kanazawa T, Urabe M, Mizukami H, et al: Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cells. Cancer Gene Ther. 8:99–106. 2001. View Article : Google Scholar : PubMed/NCBI
21	Taraboletti G and Giavazzi R: Modelling approaches for angiogenesis. Eur J Cancer. 40:881–889. 2004. View Article : Google Scholar : PubMed/NCBI
22	Hase R, Miyamoto M, Uehara H, et al: Pigment epithelium-derived factor gene therapy inhibits human pancreatic cancer in mice. Clin Cancer Res. 11:8737–8744. 2005. View Article : Google Scholar : PubMed/NCBI
23	Yang LP, Cheng P, Peng XC, et al: Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanoma. J Exp Clin Cancer Res. 28:752009. View Article : Google Scholar : PubMed/NCBI
24	Wu QJ, Gong CY, Luo ST, et al: AAV-mediated human PEDF inhibits tumor growth and metastasis in murine colorectal peritoneal carcinomatosis model. BMC Cancer. 12:1292012. View Article : Google Scholar : PubMed/NCBI
25	Stellmach V, Crawford SE, Zhou W and Bouck N: Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA. 98:2593–2597. 2001. View Article : Google Scholar : PubMed/NCBI
26	Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI